Complete Genomics, Inc. (GNOM) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St futures gain as oil slips; telecoms pressured by SpaceX spectrum deal
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Chipotle, Starbucks shares volatile after report of potential takeover
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Join SI Premium – FREE
Complete Genomics, Inc. (NASDAQ: GNOM) reported Q4 EPS of ($0.67), $0.02 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.15 million.
Sees sequencing 1,100-1,300 genomes during Q1.
For earnings history and earnings-related data on Complete Genomics, Inc. (GNOM) click here.
Sees sequencing 1,100-1,300 genomes during Q1.
For earnings history and earnings-related data on Complete Genomics, Inc. (GNOM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Valero stock set for record profit as global fuel shortage widens
- William Blair on SpaceX (SPCX): 'Indoor Coverage Problem Closer to Solved?'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
